DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d9sxbk/antifungals) has announced the addition of the "Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth" report to their offering.
Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth, which provides an insight into antifungals sales and price forecasts until 2017. The report examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. In addition, the geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report.
The report also includes insights into the Research and Development (R&D) pipeline and the potential future blockbusters until 2017 with in-depth analysis of the top three antifungal therapeutic indications, namely aspergillosis, dermatophytosis and candidiasis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications.
The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies is also presented.
The authors predict that the global antifungals market will grow at a moderate rate due to the impact of generic erosion in the dermatophytosis and candidiasis markets. There is no dominant player in the market, which is highly fragmented. Although it was worth $9.4 billion in 2010, the majority of revenues came from generic products and not from the branded products.
The fall in the dermatophytosis and candidiasis market revenues is due to the fact that drugs and topical creams such as butenafine, ciclopirox (Loprox), ciclopirox (Penlac), clotrimazole (Lotrimin), econazole (Spectazole), ketoconazole cream, miconazole (Monistat, Micatin), nystatin (Mycostatin), terbinafine (Lamisil) and tolnaftate have expired and the majority of drugs are generic.
Companies Mentioned
Ferrer Internacional S.A.
BioDelivery Sciences International, Inc.
Pfizer Inc.
Merck & Co Inc
Astellas Pharma Inc
For more information visit http://www.researchandmarkets.com/research/d9sxbk/antifungals
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
